BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1336 related articles for article (PubMed ID: 25848915)

  • 1. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
    Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
    Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
    Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
    Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
    Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
    Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
    [No Abstract]   [Full Text] [Related]  

  • 11. Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
    Adams CM; Eischen CM
    Cell Death Differ; 2016 Aug; 23(8):1312-21. PubMed ID: 26915294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
    Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
    Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.